LivingGLP1
parallel randomized trial

S002888

Design

Randomized
100
Start year
2021
Treatment
24 weeks, follow-up 24 weeks
Countries
China (1 sites)
Sponsor
(non industry)
Eligibility
BMI 28 or more; no diagnosed diabetes; no weight or insulin sensitivity drugs in prior 3 months

Conduct and analysis

Blinding
not reported
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
randomized
Missing data
none

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1liraglutide
Liraglutide plus metformin
metformin 1500 mg daily; 500 kcal deficit diet and 150 min weekly exercise advice; lifestyle: standard5050
A2Standard care or no added treatment
Metformin alone (control)
metformin 1500 mg daily; 500 kcal deficit diet and 150 min weekly exercise advice; lifestyle: standard5050

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticLiraglutide plus metformin
A1
Standard care or no added treatment
A2
agemean (years)34.8035.78
agesd (years)9.6012.89
bmimean (kg/m2)36.3434.67
bmisd (kg/m2)3.574.29
femalen3027
hba1cmedian (percent)6.155.60
hba1cq1 (percent)5.685.20
hba1cq3 (percent)6.906.09
sbpmean (mmHg)141.38139.26
sbpsd (mmHg)16.3914.88
weightmean (kg)104.4198.68
weightsd (kg)15.3417.02

Results

4 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Percent body weight change (2 lines; O10)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
24A1percent change-14.45 percent50not stated; randomized; R0003281:Results
24A2percent change-11.32 percent50not stated; randomized; R0003281:Results
Discontinuation due to adverse events (2 lines; O26)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 50not stated; randomized; R0003281:Methods
A2events0 / 50not stated; randomized; R0003281:Methods